Xenetic Biosciences Inc. (XBIO) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Xenetic Biosciences Inc. (NASDAQ: XBIO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $2.06 (+0.49% 1D, market cap $4.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, XBIO ranks #743 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XBIO carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -30.3%. By comparison, CANF (Can-Fite Biopharma Ltd each representing two (2)) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $4.9M) and AZTR (Azitra Inc) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M). Among the 5-stock peer group, XBIO leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).
Per XBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001534525), Xenetic Biosciences Inc. generated $3.0M in revenue (+19.0% YoY), -$2.7M in net income, and -$2.3M in free cash flow against $8.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
FRED Regime × Technicals: 14% of 52W Range • RSI-14 at 44 (NEUTRAL RANGE)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While XBIO currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.78) and Max Pain ($2.16) forces dealer call-delta covering toward $5.19.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Xenetic Biosciences Inc. (XBIO) advanced +0.49% to $2.06, trading at 14% of its 52-week range ($1.58 – $4.94). Stretched risk/reward at current multiples (-30% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Xenetic Biosciences Inc. (XBIO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Xenetic Biosciences Inc. (XBIO) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Xenetic Biosciences Inc. (XBIO) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Xenetic Biosciences Inc. (XBIO) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Xenetic Biosciences Inc. (XBIO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Xenetic Biosciences Inc. (XBIO) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Xenetic Biosciences Inc. (XBIO) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Xenetic Biosciences Inc. (XBIO) market action, institutional positioning, and fundamental catalysts.
Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +19.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on XBIO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for XBIO. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Xenetic Biosciences Inc. (XBIO) ranks #743 by composite RQD confidence (32/100, grade E) and #948 by equity capitalization ($4.8M). Within this direct 5-issuer industry benchmark cohort, XBIO leads on earnings valuation at N/A trailing P/E, while APUS leads on capital efficiency and profitability with -6.2% ROIC and — gross margin. APUS currently holds the highest overall quantitative score in the immediate peer group at 37/100 (D-) compared with XBIO at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| XBIO
ACTIVE
Xenetic Biosciences Inc. | E | 32/100 | — | — | -30.3% | +0.49% | $4.8M | Benchmark Subject |
| CANF Can-Fite Biopharma Ltd each representing two (2) | E | 25/100 | — | — | -35.0% | +0.62% | $4.9M | /canf-vs-xbio → |
| AZTR Azitra Inc | E | 33/100 | — | — | -35.0% | +8.72% | $4.7M | /aztr-vs-xbio → |
| APUS Apimeds Pharmaceuticals US Inc. | D- | 37/100 | — | — | -6.2% | -3.99% | $4.6M | /apus-vs-xbio → |
| TRAW Traws Pharma Inc. | E | 31/100 | — | — | -35.0% | +1.45% | $4.5M | /traw-vs-xbio → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Xenetic Biosciences Inc. (XBIO) reported GAAP revenue of $3.0M (+19.0% vs. FY2024 revenue of $2.5M , and +17.2% cumulative change since FY2023) , GAAP net income of -$2.7M, operating cash flow of -$2.3M, and free cash flow of -$2.3M (+18.8% YoY). On the balance sheet, XBIO closed FY2025 with $8.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $3.0M | -$2.7M | -$2.3M | -$2.3M | $8.4M | — |
| FY2024 (FY) | 2024-12-31 | $2.5M | -$4.0M | -$2.8M | -$2.8M | $6.9M | — |
| FY2023 (FY) | 2023-12-31 | $2.5M | -$4.1M | -$4.1M | -$4.1M | — | — |
As of 2026-11-03, Xenetic Biosciences Inc. (NASDAQ: XBIO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $2.06 (+0.49% 1D, market cap $4.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, XBIO ranks #743 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XBIO carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -30.3%. By comparison, CANF (Can-Fite Biopharma Ltd each representing two (2)) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $4.9M) and AZTR (Azitra Inc) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M). Among the 5-stock peer group, XBIO leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).
Per XBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001534525), Xenetic Biosciences Inc. generated $3.0M in revenue (+19.0% YoY), -$2.7M in net income, and -$2.3M in free cash flow against $8.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
XBIO last traded at $2.06 (+0.49% on volume of 29,702 shares), positioning the stock -25.90% below its 50-day simple moving average ($2.78) and -27.46% below its 200-day simple moving average ($2.84). Across its 52-week range of $1.58 to $4.94, XBIO sits at the 14.3% percentile with a 14-day RSI of 44.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.80 to $2.32).
Xenetic Biosciences Inc. (XBIO) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.06 (+0.49% 1D, market capitalization $4.8M).
Xenetic Biosciences Inc. (XBIO) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. The company's market capitalization is $0.0B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Xenetic Biosciences Inc. (XBIO) reported $3.0M in annual revenue (up from $2.5M in FY2024, +19.0% YoY) and -$2.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.5M revenue, -$4.1M net income) through FY2025, XBIO scaled operating cash flow to -$2.3M and free cash flow to -$2.3M, backed by $8.4M in total assets against $0 in total debt.
No upstream or downstream dependencies, sector correlations, or second-order bottleneck links are recorded.
Real-time company headlines, analyst actions, and sector developments for Xenetic Biosciences Inc. (XBIO) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Xenetic Biosciences Inc. (XBIO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Xenetic Biosciences Inc. (XBIO) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Xenetic Biosciences Inc. (XBIO) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Xenetic Biosciences Inc. (XBIO) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Xenetic Biosciences Inc. (XBIO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Xenetic Biosciences Inc. (XBIO) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Xenetic Biosciences Inc. (XBIO) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Xenetic Biosciences Inc. (XBIO) market action, institutional positioning, and fundamental catalysts.
Picked up a starter position in XBIO in my $100K Virtual Cash book at $2.05. The company has a live clinical-stage catalyst, a first patient dosed in an investigator-initiated lymphoma study, that could re-rate a stock trading at a $5.0M market cap.. Trading inside a $1.58–$4.94 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
Both sides have a point here — XBIO's 11/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Operating losses have run every year from FY 2023 to FY 2025, with ROIC at -30.3% and FCF yield at 0%, against a Strong Sell RQD score of 34.. Look at the math on XBIO: paying current EV/EBITDA multiples for -30.3% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $1.80 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: